Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ASCUS

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: ASCUS. Displaying page 1 of 1.
    EudraCT Number: 2013-003358-25 Sponsor Protocol Number: PC10VAC02 Start Date*: 2013-11-25
    Sponsor Name:Genticel
    Full Title: A double-blind, randomised, placebo-controlled, Phase II study to evaluate ProCervix efficacy to clear HPV 16 and HPV 18 infection in women with normal cytology or ASCUS/LSIL
    Medical condition: Women infected by HPV 16 and/or HPV 18 with normal cytology or ASCUS/LSIL
    Disease: Version SOC Term Classification Code Term Level
    17.1 10022891 - Investigations 10064328 Human papilloma virus test positive PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) GB (Completed) FI (Completed) DE (Completed) NL (Ongoing) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019902-17 Sponsor Protocol Number: BAY86-5300/14701 Start Date*: 2010-12-09
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multicenter, open-label, randomized, controlled, two-arm study to assess compliance with daily tablet intake of women on treatment with the oral contraceptive SH T00186D/BAY 86-5300 (0.02 mg ethi...
    Medical condition: Contraception
    Disease: Version SOC Term Classification Code Term Level
    12.1 10030970 Oral contraception LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003131-16 Sponsor Protocol Number: 20584 Start Date*: 2021-01-25
    Sponsor Name:Bayer AG
    Full Title: A randomized, double-blind, open for active comparator, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of three different doses of P2X3 antagonist (BAY 1817080) versus...
    Medical condition: Treatment of pain related to endometriosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10014788 Endometriosis related pain LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) SK (Completed) FI (Completed) NO (Completed) AT (Completed) LT (Completed) PL (Completed) BE (Completed) BG (Prematurely Ended) HU (Completed) GR (Completed) EE (Completed) LV (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004221-41 Sponsor Protocol Number: BAY1002670/17541 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, parallel-group, double-blind placebo-controlled and open label active-controlled, multi-center study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids
    Medical condition: Leiomyoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10046784 Uterine fibroids LLT
    17.1 100000004864 10016628 Fibroids LLT
    17.1 100000004864 10022794 Intramural leiomyoma of uterus LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) DE (Completed) PT (Completed) NL (Completed) GB (Completed) FI (Completed) AT (Completed) CZ (Completed) HU (Completed) LT (Completed) BE (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000059-38 Sponsor Protocol Number: 21810 Start Date*: 2021-11-17
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 52 weeks in postmenopausal women.
    Medical condition: Vasomotor symptoms associated with menopause
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10050903 Postmenopausal symptoms LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) FI (Completed) DK (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023911-32 Sponsor Protocol Number: BAY86-5028 / 13363 Start Date*: 2011-05-04
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multicenter, open-label, randomized, controlled parallel-group study to assess discontinuation rates, bleeding patterns, user satisfaction and adverse event profile of LCS12 in comparison to etonog...
    Medical condition: The aim of the present study is to examine the discontinuation rates in women (ages 18-35, inclusive) using LCS12 compared with the discontinuation rates in women using the ENG subdermal contracept...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10010808 Contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) FI (Completed) GB (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2020-004855-34 Sponsor Protocol Number: 21652 Start Date*: 2021-11-25
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women
    Medical condition: Vasomotor symptoms associated with menopause
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10050903 Postmenopausal symptoms LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) NO (Completed) PT (Completed) SK (Completed) PL (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004908-33 Sponsor Protocol Number: 21651 Start Date*: 2021-10-18
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women
    Medical condition: Vasomotor symptoms associated with menopause
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038604 - Reproductive system and breast disorders 10050903 Postmenopausal symptoms LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) IT (Completed) HU (Completed) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001269-18 Sponsor Protocol Number: VMT-VT-1161-CL-011 Start Date*: 2019-03-13
    Sponsor Name:Mycovia Pharmaceuticals, Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects with Recurrent Vulvovaginal Candidiasis
    Medical condition: Recurrent Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: BG (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020181-21 Sponsor Protocol Number: BAY86-5028/13362 Start Date*: 2011-01-13
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multicenter, randomized, open-label, parallel-group study to evaluate user satisfaction with and tolerability of the low-dose levonorgestrel (LNG) intrauterine delivery system (IUS) with 12 µg LNG/...
    Medical condition: The aim of the present study is to examine the overall satisfaction with and tolerability of LCS12 compared with a standard combined oral contraceptive (COC; Yasmin; 30 µg ethinyl estradiol and 3 m...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10010808 Contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001270-26 Sponsor Protocol Number: VMT-VT-1161-CL-012 Start Date*: 2018-12-12
    Sponsor Name:Mycovia Pharmaceuticals, Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects with Recurrent Vulvovaginal Candidiasis
    Medical condition: Recurrent Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-002065-37 Sponsor Protocol Number: BAY86-5028 / 14371 Start Date*: 2011-09-12
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multi-center, single-arm study to assess the safety, efficacy, discontinuation rate and pharmacokinetics of the low-dose levonorgestrel intrauterine contraceptive system (LCS12) in post-menarcheal ...
    Medical condition: Contraception
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10010808 Contraception PT
    Population Age: Adolescents, Under 18 Gender: Female
    Trial protocol: SE (Completed) FI (Completed) NL (Completed) AT (Completed) BE (Completed) DE (Completed) DK (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2004-005173-27 Sponsor Protocol Number: 0858A4-318-WW Start Date*: 2005-10-21
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF A COMBINATION OF LEVONORGESTREL AND ETHINYL ESTRADIOL IN A CONTINUOUS DAILY REGIMEN IN SUBJECTS WITH PREMENSTRUAL DYSPHORIC DISO...
    Medical condition: Premenstrual dysphoric disorder (PMDD) affects 3% to 5% of menstruating women. PMDD is defined by markedly depressed mood, anxiety, and/or affective lability during the last week of the late lutea...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) FI (Completed) SE (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003226-42 Sponsor Protocol Number: 91550 Start Date*: 2008-12-10
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multicenter, randomized, double-blind, active-controlled, parallel group, 2-arm study to investigate the effect of estradiol valerate/dienogest compared to Microgynon on hormone withdrawal associ...
    Medical condition: Hormone withdrawal associated symptoms of headache and pelvic pain suffered by patients receiving LNG containing oral contraception.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10030970 Oral contraception LLT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) DE (Completed) ES (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006946-24 Sponsor Protocol Number: NV25025 Start Date*: 2009-12-10
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high...
    Medical condition: High grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049701 Cervical intraepithelial neoplasia II LLT
    9.1 10049702 Cervical intraepithelial neoplasia III LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FI (Completed) ES (Completed) BE (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2017-000244-18 Sponsor Protocol Number: BAY1128688/17472 Start Date*: 2017-09-25
    Sponsor Name:Bayer AG
    Full Title: A randomized, placebo-controlled, double-blind, parallel-group, multi-center, exploratory dose-response study to assess the efficacy and safety of different oral doses of BAY 1128688 in women with ...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014788 Endometriosis related pain LLT
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002855-48 Sponsor Protocol Number: BAY1002670/15789 Start Date*: 2017-07-12
    Sponsor Name:Bayer AG
    Full Title: A randomized, parallel-group, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids
    Medical condition: Leiomyoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046784 Uterine fibroids LLT
    20.0 100000004864 10016628 Fibroids LLT
    20.0 100000004864 10022794 Intramural leiomyoma of uterus LLT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed) SE (Completed) CZ (Completed) HU (Prematurely Ended) FI (Completed) AT (Prematurely Ended) NO (Prematurely Ended) DE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) DK (Completed) BE (Completed) SK (Completed) LT (Completed) NL (Prematurely Ended) PT (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 10:28:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA